The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. In the phase 2 part of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback